Louis Philipson
Endocrinology, Diabetes & Metabolism · Chicago, ILNPI 1093877540
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $15,725 of the $18,995 with a category attached, or 82.8%. Abbott accounts for 79.1% of it on its own, with 4 other manufacturers making up the rest. 2025 is the largest year on record at $15,060, more than ten times the $1,165 reported in 2020.
Across 32 payments — averaging $593.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$15K
- Nevro Corp.$4K
- Novo Nordisk$65
- Bayer$33
- Mannkind Corporation$20
Across 338 payments — averaging $642.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$76K
- Dompe Farmaceutici S.p.a.$67K
- Novartis$34K
- Bayer$24K
- Janssen Research & Development, LLC$17K
What the payments were for
- Consulting fees$15,72583%
- Travel & lodging$2,18011%
- Food & beverage$1,0055%
- Education$850%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 23 | $15,027 |
| Nevro Corp. | 4 | $3,850 |
| Novo Nordisk | 2 | $65 |
| Bayer | 2 | $33 |
| Mannkind Corporation | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnia$2,750
- Senza Spinal Cord Stimulation System$1,100
How this compares
$18,995 in reported general payments places this provider in the 85th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
See all endocrinology, diabetes & metabolism providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 73 | $112,348 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 45 | $65,269 |
| OzempicSemaglutide | 26 | $54,177 |
| Humalog Kwikpen U-200Insulin Lispro | 14 | $51,194 |
| JardianceEmpagliflozin | 19 | $32,523 |
| FarxigaDapagliflozin Propanediol | 17 | $28,649 |
| Novolog FlexpenInsulin Aspart | 31 | $12,107 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 14 | $10,748 |
| NovologInsulin Aspart | 20 | $9,676 |
| HumalogInsulin Lispro | 40 | $8,911 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 19 | $7,870 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 41 | $7,724 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $7,416 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 39 | $5,332 |
| Humalog Kwikpen U-100Insulin Lispro | 20 | $4,272 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $65 | $63,85346 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
Other endocrinology, diabetes & metabolism in Chicago
- Wahid KassarChicago$884K
- George BakrisChicago$403K
- Wenyu HuangChicago$341K
- Silvana PannainChicago$226K
- Grazia AleppoChicago$162K
- Tamara VokesChicago$139K
- Emily SmithChicago$112K
- Antonio BiancoChicago$111K
- Aaron BenjaminChicago$105K
- David OyerChicago$101K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.